Prothrombin (factor II) and fragment 1+2 (F1+2)
Maruyama, I.
Nihon Rinsho. Japanese Journal of Clinical Medicine 57 Suppl: 579-581
1999
ISSN/ISBN: 0047-1852 PMID: 10543183 Document Number: 504752
Document emailed within 1 workday
Related Documents
Kyrle, P.A.; Eichinger, S.; Pabinger, I.; Stümpflen, A.; Hirschl, M.; Bialonczyk, C.; Schneider, B.; Mannhalter, C.; Melichart, M.; Traxler, G.; Weltermann, A.; Speiser, W.; Lechner, K. 1997: Prothrombin fragment F1+2 is not predictive for recurrent venous thromboembolism Thrombosis and Haemostasis 77(5): 829-833Fota-Markowska, H.; Modrzewska, R.; Krzowska-Firych, J.; Lis-Tønder, J.; Borowicz, I. 2004: Concentration of prothrombin fragment 1 + 2 (f1 + 2) in patients with liver cirrhosis and chronic hepatitis C infection Annales Universitatis Mariae Curie-Sklodowska. Sectio D: Medicina 59(2): 4-7
Rifón, J.; Collados, M.T.; Montes, R.; Chordá, C.; Páramo, J.A.; Rocha, E. 1992: Thrombin-antithrombin complexes and F1+2 prothrombin fragment in coronary revascularization surgery. Relationship with graft occlusion Sangre 37(4): 259-263
Wilkes, H.C.; Meade, T.W.; Barzegar, S.; Foley, A.J.; Hughes, L.O.; Bauer, K.A.; Rosenberg, R.D.; Miller, G.J. 1992: Gemfibrozil reduces plasma prothrombin fragment F1 + 2 concentration, a marker of coagulability, in patients with coronary heart disease Thrombosis and Haemostasis 67(5): 503-506
Tientadakul, P.; Opartkiattikul, N.; Sangtawesin, W.; Sakiyalak, P. 1997: Effect of different oral anticoagulant intensities on prothrombin fragment 1 + 2 in Thai patients with mechanical heart valve prostheses Journal of the Medical Association of Thailand 80(2): 81-86
Takeda, Y. 1970: Studies of the effects of heparin, Coumadin, and vitamin K on prothrombin metabolism and distribution in calves with the use of iodine-125-prothrombin. Characterization of the prothrombin system Journal of Laboratory and Clinical Medicine 75(3): 355-381
Kienast, J.; Thompson, S.G.; Raskino, C.; Pelzer, H.; Fechtrup, C.; Ostermann, H.; van de Loo, J. 1993: Prothrombin activation fragment 1 + 2 and thrombin antithrombin III complexes in patients with angina pectoris: relation to the presence and severity of coronary atherosclerosis Thrombosis and Haemostasis 70(4): 550-553
Leroy-Matheron, C.; Gouault-Heilmann, M. 1994: Influence of conditions of blood sampling on coagulation activation markers (prothrombin fragment 1 + 2, thrombin-antithrombin complexes and D-dimers) measurements Thrombosis Research 74(4): 399-407
Philippou, H.; Adami, A.; Lane, D.A.; MacGregor, I.R.; Tuddenham, E.G.; Lowe, G.D.; Rumley, A.; Ludlam, C.A. 1996: High purity factor IX and prothrombin complex concentrate (PCC): pharmacokinetics and evidence that factor IXa is the thrombogenic trigger in PCC Thrombosis and Haemostasis 76(1): 23-28
Sakurada, T.; Kojima, S.; Oishi, D.; Koitabashi, K.; Miyamoto, M.; Shirai, S.; Shibagaki, Y.; Yasuda, T.; Sato, T.; Kimura, K. 2011: Prothrombin fragment 1 + 2 (F1 + 2) in effluent is a useful marker for peritoneal permeability in peritoneal dialysis patients using neutral dialysate Advances in Peritoneal Dialysis. Conference on Peritoneal Dialysis 27: 2-5
Gordon, E.M.; Hellerstein, H.K.; Ratnoff, O.D.; Arafah, B.M.; Yamashita, T.S. 1987: Augmented Hageman factor and prolactin titers, enhanced cold activation of factor VII, and spontaneous shortening of prothrombin time in survivors of myocardial infarction Journal of Laboratory and Clinical Medicine 109(4): 409-413
Ono, M.; Ohta, H.; Ohhira, M.; Sekiya, C.; Namiki, M. 1990: Measurement of immunoreactive prothrombin, des-gamma-carboxy prothrombin, and vitamin K in human liver tissues: overproduction of immunoreactive prothrombin in hepatocellular carcinoma American Journal of Gastroenterology 85(9): 1149-1154
Koefoed, B.G.; Feddersen, C.; Gulløv, A.L.; Petersen, P. 1997: Effect of fixed minidose warfarin, conventional dose warfarin and aspirin on INR and prothrombin fragment 1 + 2 in patients with atrial fibrillation Thrombosis and Haemostasis 77(5): 845-848
Tripodi, A.; Cattaneo, M.; Molteni, A.; Cesana, B.M.; Mannucci, P.M. 1998: Changes of prothrombin fragment 1+2 (F 1+2) as a function of increasing intensity of oral anticoagulation--considerations on the suitability of F 1+2 to monitor oral anticoagulant treatment Thrombosis and Haemostasis 79(3): 571-573
Alakhov, I.B.; Bundule, M.A.; Bundulis, I.P.; Vinokurov, L.M.; Kozlov, V.P. 1983: Primary structure of the elongation factor G from Escherichia coli. VIII. Structure of tryptic peptides comprising the T4 fragment of limited trypsinolysis of the G-factor Bioorganicheskaia Khimiia 9(3): 330-342
Akhavan, S.; Lavoretano, S.; Chantarangkul, V.; Mannucci, P.M. 2002: Plasma prothrombin levels are not associated with mutations in the promoter region of the prothrombin gene Thrombosis and Haemostasis 88(5): 877-878
Rao, L.V.; Hoang, A.D.; Rapaport, S.I. 1995: Differences in the interactions of lupus anticoagulant IgG with human prothrombin and bovine prothrombin Thrombosis and Haemostasis 73(4): 668-674
Shah, D.V.; Engelke, J.A.; Suttie, J.W. 1993: Prothrombin synthesis in rat hepatoma H4IIEC3 cells: response to the proposed "coagulopoietin factor" Thrombosis and Haemostasis 69(4): 328-330
Reuner, K.H.; Ruf, A.; Grau, A.; Rickmann, H.; Stolz, E.; Jüttler, E.; Druschky, K.F.; Patscheke, H. 1998: Prothrombin gene G20210-->A transition is a risk factor for cerebral venous thrombosis Stroke 29(9): 1765-1769
Jaekel H.-P.; Trabandt A.; Schmid D.; Grobe N.; Müller E.-W.; Ziutelis V.; Kaskel-Paul S.; Höh H.; Bauer B.; Sudik R.; Baldauf A.; Werle E. 2004: Autoantibodies to Prothrombin and Phosphatidylserine/Prothrombin-Complexes: Do they contribute to the Serodiagnosis of Primary and Secondary Anti-Phospholipid Syndrome? Clinical Laboratory 50(5-6): 295-304